Key words
pregnancy - gestational thrombocytopenia - idiopathic thrombocytopenic purpura - hypertensive
disorders of pregnancy
Schlüsselwörter
Schwangerschaft - schwangerschaftsassoziierte Thrombozytopenie - idiopathische thrombozytopenische
purpura - hypertensive Schwangerschaftserkrankungen
Introduction
Pregnancy triggers various biological mechanisms that affect hematopoietic and related
systems [1]. Thrombocytopenia is the second most common hematologic disorder after anemia [2]. The incidence of thrombocytopenia during pregnancy has been shown to be between
6 and 10% and is defined as a platelet count < 150 × 103/µl [3]. Gradual decreases in thrombocyte counts are observed during pregnancy, but most
of these changes are within physiological levels [4]. Despite the lack of consensus, this mild, physiological decrease has been mostly
explained by dilution, decreased production, pooling at placental and splenic circulation,
or increased turnover of platelets [5], [6]. These pathophysiological pathways mostly end in mild thrombocytopenia, which is
not related to maternal or neonatal complications. Differential diagnosis is critical
in the management of patients with idiopathic thrombocytopenic purpura (ITP) or hypertensive
disorders of pregnancy (HDP) since they are managed differently and have different
outcomes; these conditions are the most common etiological factors in clinically important
thrombocytopenia during pregnancy [7].
Gestational thrombocytopenia (GT) is a self-limiting benign condition, which mostly
is not related to adverse outcomes and requires no additional evaluation or intervention
[8], [9]. GT comprises up to 75% of all cases of thrombocytopenia in pregnancy [10]. The incidence of GT in moderate and severe thrombocytopenia is mostly decreased
since GT is primarily associated with mild thrombocytopenia, which is most commonly
diagnosed in the 3rd trimester [11]. Diagnosis of GT is usually incidental, presenting with no clinical signs or symptoms
[12]. The diagnosis of GT is one of exclusion, which has no additional findings and resolves
quickly in the postpartum period without any prior history of thrombocytopenia before
pregnancy [13]. Severe thrombocytopenia, mostly below 100 × 103/µl or 70 × 103/µl are mostly not related with GT [14], [15]. In cases where platelet counts are below these thresholds, other diagnoses must
be carefully considered.
ITP is also relatively uncommon with an incidence of 1 in 1000 to 10 000 pregnancies
[16]. The rate of ITP is nearly 10-fold greater than the rate in the nonpregnant population
which is mostly related to increased turnover of platelets in pregnancy [17]. ITP occurs due to the destruction of circulating platelets via antiplatelet antibodies
and may worsen during pregnancy, which can result in the development of severe thrombocytopenia
[18], [19]. The maternal immunoglobulins that cause ITP are of the IgG type, which may cross
the placenta and may also lead to neonatal thrombocytopenia. Previous studies have
found that newborns born to mothers with ITP may have platelet counts < 50 × 103/µl with a 3% rate of major bleeding complication and 1% rate of intracranial hemorrhage
[20]. The differential diagnosis between GT and ITP is challenging primarily due to the
lack of specific symptoms. Cases of thrombocytopenia before pregnancy or moderate
and severe thrombocytopenia are commonly diagnosed as ITP [21]. Under certain circumstances, such as nonpregnant patients, ITP is also treated
with corticosteroids and/or intravenous immunoglobulin (IVIG) [22]. Although corticosteroids are considered to be the first-line therapies in the management
of severe ITP, their efficacy is similar to that of IVIG [23], [24]. Treatments such as vasopressin type 2 receptor agonists are also recommended in
cases of thrombocytopenia during labor [25].
Thrombocytopenia is also a characteristic feature of hypertensive disorders of pregnancy,
including preeclampsia and HELLP syndrome, which comprise 5 – 21% of all thrombocytopenia
cases [26]. Thrombocytopenia occurs as a result of complex pathophysiological pathways resulting
in microangiopathy [27]. Despite sharing similar clinical features and results, the pathophysiology of HELLP
syndrome has also some unique characteristics [28]. Thrombocytopenia is found to occur in 50% of patients with preeclampsia [15]. A platelet count < 100 × 103/µl is considered to be a criterion for severe preeclampsia and a diagnostic tool
for the management of preeclampsia [29]. In order to reduce maternal and fetal complications, delivery is the treatment
option for severe preeclampsia and HELLP for reducing maternal and fetal complications
[30].
In this study, we evaluated the most common etiological factors for thrombocytopenia
in pregnancy. We aimed to show the differences between the progression of the diseases
and obstetric and neonatal outcomes in terms of etiological factors.
Materials and Methods
Study design
We retrospectively evaluated patients with a thrombocyte level < 150 000/µl, who were
hospitalized at the delivery room of our institution, between 2013 and 2018. Patient
names and file numbers were obtained from our electronic database; in total, 1474 patients,
with a thrombocyte level < 150 000 during hospitalization at the delivery room, were
included.
Patients with a complete blood count conducted 7 days before delivery were evaluated.
The final laboratory findings taken prior to delivery including hemoglobin (Hb) levels,
platelet count, plateletcrit (PCT), Mean Platelet Volume (MPV), and Platelet Distribution
Width (PDW) were also recorded as the laboratory findings prior to delivery. ALT,
AST, BUN, and serum creatinine levels were also recorded if the related blood samples
were collected prior to delivery. We have also recorded the Hb levels on the morning
of the first postpartum or postoperative day as the postpartum Hb levels.
Inclusion and exclusion criteria
Etiological factors were evaluated according to follow-up of patients in our department
and the hematology department. Patients with gestational thrombocytopenia, ITP, and
hypertensive disorders of pregnancy were included in this study. Patients with any
other chronic systemic disease or any pathology that may cause thrombocytopenia such
as HUS, thrombotic thrombocytopenic purpura (TTP), and also lupus erythematosus, APL-Syndrome,
von-Willebrand disease type 2b were also excluded. Patients who were diagnosed with
pseudothrombocytopenia including pseudo immune thrombocytopenia according to their
peripheral blood smear and repeat blood counts were excluded. Patients without adequate
information or delivered at other institutions were also excluded. Patients with a
thrombocyte level > 150 000/µl prior to delivery were excluded from the study. Pregnancies
reaching the 22nd gestational week or a fetal weight of 550 g were included in order
to see the delivery outcomes. The lowest platelet count during the pregnancy was also
recorded. Patients without adequate laboratory findings were also excluded from the
study. Patients with a prior diagnosis of bleeding diathesis, placental invasion anomalies,
or those undergoing anticoagulant therapies for any purposes were excluded from the
study to prevent any bias related to postpartum results.
After the application of these inclusion and exclusion criteria, 385 patients met
all criteria for inclusion. The gestational week at birth, birthweight, route of delivery,
and Apgar scores at the 1st and 5th minutes were also recorded as obstetric outcomes.
Procedures
All of the laboratory findings during the whole pregnancy were retrospectively screened.
The timing of the initial thrombocytopenia diagnosis was recorded according to trimesters.
Platelet counts prior to delivery were classified as < 50 000; 50 000 – 100 000; and
> 100 000, which are defined as mild, moderate, and severe thrombocytopenia, respectively
[11]. Any medical intervention during the antenatal period to improve platelet counts
was also recorded. Oral prednisolone and intravenous immunoglobulin therapies were
applied with initial doses of 1 mg/kg and 1 g/kg, respectively according to practice
guidelines of the American Society of Hematology [31]. Treatment indications were similar to the non-pregnant population as recommended
in recent literature.
All transfusions of blood products and cellular blood components were recorded and
evaluated. Pregnancies that were complicated with postpartum hysterectomies were also
recorded. The platelet count of the newborns within the 24 hours after delivery was
also recorded if data was available. Fetuses that were diagnosed as thrombocytopenic
(< 150 000/µl) were also evaluated for any complications related to thrombocytopenia.
Further comparisons were performed between the groups according to etiology (gestational
thrombocytopenia, ITP, or hypertensive disorders of pregnancy), time of initial diagnosis
(1st, 2nd, or 3rd trimester), and platelet count prior to delivery (mild, moderate,
and severe) in terms of maternal age, rate of nulliparous cases, minimal platelet
count during pregnancy, laboratory findings prior to delivery (platelet count, PCT,
MPV, PDW, ALT, AST, BUN, and serum creatinine levels), Hb reduction at delivery, any
blood product transfusion, and newborn platelet counts.
Diagnostic criteria
Gestational thrombocytopenia was considered to be a diagnosis by exclusion with symptoms
initially diagnosed at gestation, no prior history of thrombocytopenia, and no related
diseases according to examinations performed by obstetricians and hematologists. Gestational
thrombocytopenia diagnosis was excluded in cases in which thrombocytopenia persisted
for 6 weeks after delivery or between other pregnancies of patients. A diagnosis of
ITP was made by the hematology department relying on the previous history of patients
and peripheral blood smears according to international guidelines [31]. Antiplatelet antibodies were not used for the diagnosis of ITP due to low sensitivity
and specificity [31]. Hypertensive disorders of pregnancy were also diagnosed according to international
guidelines [32].
Statistical analysis
The acquired data was used for descriptive analysis. The data are presented as median
(range) or frequencies. Further comparisons between groups were performed by Kruskal-Wallis
test or χ2 test according to variable characteristics. Statistical analyses were performed using
SPSS v23.0 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0
Armonk, NY: IBM Corp.). Further pair-wise comparisons were performed between groups
by Mann-Whitney U and Chi-Square test in case of significant difference between groups.
A p-value < 0.05 was considered to be statistically significant.
This retrospective study was approved by Hacettepe University Ethics Committee (GO:
18/884)
Results
Descriptive statistics
We evaluated the pregnancy outcomes and laboratory findings of 385 patients diagnosed
with gestational thrombocytopenia, ITP, or hypertensive disorders of pregnancy ([Table 1]). Median values of minimal platelet counts during pregnancy and platelet counts
prior to delivery were determined as 130 (7 – 149) and 131 (36 – 149), respectively.
Median values of Hb before and after delivery were 12.2 (8.2 – 16) and 10.6 (2 – 15),
respectively. Median gestational week at birth and birthweight were also determined
as 38 (22 – 41) and 3180 (550 – 5050), respectively. The majority of patients were
found to have been initially diagnosed during the 3rd trimester (77.2%). Gestational
thrombocytopenia, ITP, and preeclampsia were the final diagnosis for 315 (81.8%),
35 (9.1%) and 35 (9.1%) cases, respectively. Any kind of blood product transfusion
was performed in 38 (9.9%) cases. The most commonly used blood product was packed
red blood cells which were used in 23 cases.
Table 1 Characteristics, obstetric outcomes and thrombocytopenia related information about
the cases.
|
Median (Range)
|
|
* Rate of event has been given.
|
|
Maternal age
|
31 (19 – 45)
|
|
Gravida
|
2 (1 – 14)
|
|
Parity
|
1 (0 – 4)
|
|
Abortus
|
0 (0 – 12)
|
|
Minimal platelet count during pregnancy
|
130 (7 – 149)
|
|
Laboratory findings prior to delivery
|
|
|
|
131 (36 – 149)
|
|
|
0.127 (0.006 – 0.219)
|
|
|
10 (7.1 – 14.8)
|
|
|
18.1 (8.1 – 20.4)
|
|
Hemoglobin levels (mg/dL)
|
|
|
|
12.2 (8.2 – 16)
|
|
|
10.6 (2 – 15)
|
|
Route of delivery*
|
|
|
|
37 (9.6%)
|
|
|
348 (90.4%)
|
|
Birthweight
|
3180 (550 – 5050)
|
|
Gestational week at delivery
|
38 (22 – 41)
|
|
Apgar scores
|
|
|
|
9 (0 – 10)
|
|
|
10 (0 – 10)
|
|
Initial diagnosis of thrombocytopenia*
|
|
|
|
33 (8.6%)
|
|
|
55 (14.2%)
|
|
|
297 (77.2%)
|
|
Diagnosis*
|
|
|
|
315 (81.8%)
|
|
|
35 (9.1%)
|
|
|
35 (9.1%)
|
|
Transfusion*
|
38 (9.9%)
|
|
Amount of transfusion (units)
|
|
|
|
4 (2 – 13)
|
|
|
11 (6 – 32)
|
|
|
2 (1 – 5)
|
|
|
6 (3 – 35)
|
|
Postpartum hysterectomy*
|
4 (1%)
|
|
Newborn platelet count (n = 179)
|
212.5 (33 – 376)
|
A total of 12 patients had undergone medical treatments during the antenatal period
including methylprednisolone and/or IVIG at different doses. All of the patients that
had undergone medical treatment were also found to have ITP. None of the patients
required further medical treatment or a splenectomy during the pregnancy. Median platelet
counts prior to treatment and one week after the treatment were determined as 38.5
(7 – 66) and 68 (37 – 150), respectively.
Four patients underwent a postpartum hysterectomy due to refractory hemorrhage. None
of these 4 patients had been diagnosed with having severe thrombocytopenia prior to
delivery. The route of delivery was vaginal in 1 case and cesarean in the remaining
3 cases; all cases required a transfusion. Etiological factors were determined as
GT in 3 of the cases and as hypertensive disorders in the remaining case.
The platelet count of the newborn was acquired in 179 cases. The median platelet count
was 212.5 (33 – 376). A total of 38 (21.2%) newborns were evaluated as thrombocytopenic.
Comparison of groups
Patients were compared according to etiology of thrombocytopenia, gestational week
at diagnosis, and platelet counts prior to delivery. Analysis of etiological factors
revealed that patients with hypertensive disorders were significantly older than patients
of the other groups (p < 0.001). Distribution of etiological factors according to
initial time of diagnosis revealed that ITP was diagnosed at 1st trimester significantly
more common than other diseases, while the others were more commonly diagnosed at
3rd trimester compared to ITP (p < 0.001). It was also demonstrated that the minimal
platelet count during the antenatal period and the platelet count prior to delivery
were significantly lower in patients with ITP (p < 0.001; p < 0.001). PCT values were
lower and MPV and PDW values were significantly higher which were compatible with
platelet count in patients with ITP compared to other groups (p < 0.001; p = 0.002;
p = 0.006; respectively). ITP was also found to be significantly associated with moderate
and severe thrombocytopenia compared to other groups, while gestational thrombocytopenia
and hypertensive disorders of pregnancy were significantly associated with mild thrombocytopenia
(p < 0.001). Further analysis regarding serum ALT, AST, BUN, and creatinine levels
revealed significantly higher values in patients with hypertensive disorders of pregnancy
(p < 0.001). Despite the lack of statistical significance in the reduction of Hb levels
at delivery between groups, any kind of transfusion was significantly more common
in patients with ITP (p < 0.001) ([Table 2]).
Table 2 Evaluation of laboratory findings, transfusion, hemoglobin level decrement in delivery
and newborn platelet counts in terms of etiological factors.
|
Gestational thrombocytopenia (GT) (n = 315)
|
ITP (n = 35)
|
Hypertensive disorders of pregnancy (HDP) (n = 35)
|
p value
|
|
Pair-wise comparisons by Mann-Whitney U and χ2 test resulted in a p value of < 0.05
a HDP compared to GT and ITP
b ITP compared to GT and HDP in first trimester and third trimester
c
ITP compared to GT and HDP
d
GT compared to ITP and HDP
e GT compared to ITP and HDP in mild thrombocytopenia and ITP compared to GT and HDP
in moderate and severe thrombocytopenia
‡ Given for 112 cases and γ given for 179 cases where data was eligible
|
|
Maternal age
|
30 (19 – 45)
|
29 (21 – 40)
|
34 (19 – 42)
|
0.001a
|
|
Nulliparous
|
120 (38%)
|
11 (31.4%)
|
17 (48.5%)
|
0.323
|
|
Initial diagnosis of thrombocytopenia
|
|
|
|
|
|
|
5 (1.5%)
|
28 (80%)
|
0 (0%)
|
< 0.001b
|
|
|
46 (14.6%)
|
1 (2.8%)
|
8 (22.8%)
|
|
|
264 (83.8%)
|
6 (17.1%)
|
27 (77.2.%)
|
|
Minimal platelet count during pregnancy
|
133 (62 – 149)
|
56 (7 – 112)
|
113 (48 – 149)
|
< 0.001c
|
|
Laboratory findings prior to delivery
|
|
|
|
|
|
|
133 (62 – 149)
|
69 (36 – 120)
|
117 (51 – 149)
|
< 0.001c
|
|
|
0.13 (0.057 – 0.219)
|
0.073 (0.006 – 0.135)
|
0.118 (0.009 – 0.145)
|
< 0.001c
|
|
|
9.9 (7.1 – 14.8)
|
10.9 (7.3 – 14.1)
|
10.3 (7.2 – 13.7)
|
0.002c
|
|
|
18.2 (8.1 – 20.2)
|
17.8 (15.6 – 20.4)
|
17.9 (15.9 – 19.3)
|
0.006d
|
|
Severity of thrombocytopenia prior to delivery
|
|
|
|
|
|
|
296 (94%)
|
5 (14.2%)
|
27 (77.2%)
|
< 0.001e
|
|
|
19 (6%)
|
22 (62.8%)
|
8 (22.8%)
|
|
|
0
|
8 (22.8%)
|
0
|
|
Other laboratory findings prior to delivery‡
|
|
|
|
|
|
|
12 (5 – 42)
|
15 (9 – 18)
|
24 (7 – 182)
|
< 0.001 a
|
|
|
20.5 (9 – 72)
|
23 (21 – 32)
|
31 (12 – 325)
|
< 0.001 a
|
|
|
6.74 (3.2 – 14.4)
|
8.18 (4.82 – 14.4)
|
11.7 (5.15 – 21.3)
|
< 0.001 a
|
|
|
0.47 (0.24 – 0.99)
|
0.53 (0.44 – 0.82)
|
0.63 (0.34 – 1.89)
|
< 0.001a
|
|
Hb decrement during delivery (mg/dL)
|
1.6 (− 1.4 – 8.5)
|
1.5 (− 0.7 – 6.0)
|
1.3 (− 1.9 – 3.9)
|
0.985
|
|
Transfusion
|
16 (5.0%)
|
16 (45.7%)
|
6 (17.1%)
|
< 0.001c
|
|
Newborn platelet count (× 103/µl)γ
|
220 (58 – 354)
|
190 (41 – 345)
|
207 (33 – 376)
|
0.566
|
|
Newborn thrombcytopenia
|
21/119 (17.6%)
|
10/35 (28.5%)
|
7/25 (28%)
|
0.256
|
Patients were compared in terms of the timing of the initial diagnosis. Patients diagnosed
during the 1st trimester had significantly lower minimal platelet counts during the
antenatal period and prior to delivery (p < 0.001; p < 0.001). The transfusion rate
was also significantly higher in patients diagnosed during the 1st trimester than
the others, despite the lack of statistical significance between groups in terms of
reduction of Hb levels (p < 0.001; p = 0.647).
Further analysis was performed to compare patients in terms of severity of the disease.
The transfusion rate was found to be significantly higher in patients with severe
thrombocytopenia compared to mild and moderate thrombocytopenia, despite the lack
of significance in the reduction of Hb levels (p < 0.001; p = 0.647) ([Table 3]).
Table 3 Evaluation of laboratory findings, transfusion, hemoglobin level decrement in delivery
and newborn platelet counts gestational trimester at diagnosis and platelet levels
prior to pregnancy.
|
γ Given for 179 patients where data is available
Pair-wise comparisons by Mann-Whitney U and χ2 test resulted in a p value of < 0.05
a 1st trimester compared to 2nd trimester and 3rd trimester
b Severe thrombocytopenia compared to mild and moderate; moderate thrombocytopenia
compared to mild thrombocytopenia
|
|
Gestational week at diagnosis
|
1st trimester (n = 33)
|
2nd trimester (n = 55)
|
3rd trimester (n = 297)
|
|
|
Maternal age
|
28 (21 – 40)
|
31 (22 – 42)
|
31 (19 – 45)
|
0.100
|
|
Nulliparous
|
11 (33.3%)
|
22 (44.4%)
|
115 (38.7%)
|
0.806
|
|
Minimal platelet count during pregnancy
|
58 (7 – 125)
|
119 (35 – 149)
|
133 (43 – 149)
|
< 0.001a
|
|
Laboratory findings prior to delivery
|
|
|
|
|
|
|
72 (36 – 126)
|
123 (37 – 149)
|
133 (45 – 149)
|
< 0.001a
|
|
|
0.085 (0.034 – 0.155)
|
0.122 (0.009 – 0.175)
|
0.130 (0.006 – 0.219)
|
< 0.001a
|
|
|
11.2 (7.3 – 14.1)
|
10 (7.1 – 13.7)
|
9.9 (7.2 – 14.8)
|
< 0.001a
|
|
|
17.9 (10.2 – 20.4)
|
18.2 (16.3 – 19.4)
|
18.1 (8.1 – 20.2)
|
0.480
|
|
Hb decrement during delivery (mg/dL)
|
1.6 (− 0.7 – 4.6)
|
1.5 (− 1.9 – 4.6)
|
1.6 (− 1.0 – 6.0)
|
0.647
|
|
Transfusion
|
13 (39.3%)
|
5 (9.0%)
|
20 (6.7%)
|
< 0.001a
|
|
Newborn platelet countγ
|
192 (41 – 345)
|
210 (64 – 376)
|
219.5 (33 – 354)
|
0.907
|
|
Newborn thrombcytopenia
|
7/29 (24.1%)
|
7/26 (26.9%)
|
24/124 (19.3%)
|
0.634
|
|
Platelet levels prior to delivery
|
Severe thrombocytopenia (n = 8)
|
Moderate thrombocytopenia (n = 49)
|
Mild thrombocytopenia (n = 328)
|
|
|
Maternal age
|
33 (24 – 40)
|
30 (19 – 39)
|
31 (19 – 45)
|
0.515
|
|
Nulliparous
|
1 (12.5%)
|
18 (36.7%)
|
129 (39.3%)
|
0.295
|
|
Hb decrement during delivery (mg/dL)
|
2.35 (0.3 – 6.0)
|
1.5 (− 1.0 – 4.6)
|
1.65 (− 1.9 – 5.6)
|
0.647
|
|
Transfusion
|
6 (75%)
|
14 (28.5%)
|
18 (5.4%)
|
< 0.001b
|
|
Newborn platelet count (× 103/µl)γ
|
181 (115 – 278)
|
181.5 (58 – 345)
|
221.5 (33 – 376)
|
0.907
|
|
Newborn thrombcytopenia
|
4/8 (50%)
|
10/39 (25.6%)
|
24/132 (18.1%)
|
0.076
|
Analysis regarding newborn platelet levels showed no statistical difference between
any groups. None of the 38 thromboytopenic newborns required medical therapy to improve
platelet counts or had any complications related to hemorrhage, including intracranial
hemorrhages. Three out of 38 newborns died due to extreme prematurity, and 3 required
transfusions due to increased hematocrit levels (partial Exchange transfusion), Rh
incompatibility and fetal anemia. Analysis regarding etiological factors, time of
initial diagnosis, and severity of thrombocytopenia did not show any statistical significance
in terms of the rate of thrombocytopenia in newborns (p = 0.256; p = 0.634; p = 0.076;
respectively). Despite the lack of statistical significance, the rate of thrombocytopenia
in newborns was 50% in the patients with severe thrombocytopenia, while rates were
25.6 and 18.1% in patients with moderate and mild thrombocytopenia, respectively (p = 0.076).
Discussion
Thrombocytopenia in pregnancy is usually benign and is not related to obstetric and
neonatal complications. The most important determinant of the outcome has been shown
to be the etiologic factor. In this study, we compared the 3 most common etiological
factors for thrombocytopenia in pregnancy; GT, ITP, and HDP. The rate of moderate
thrombocytopenia in patients with GT was found to be 6%. Despite the fact that platelet
counts < 70 × 103/µl are less likely to be due to GT, previous studies have also shown relatively high
rates of GT diagnosis in patients with moderate and severe thrombocytopenia [33]. This study has also shown that all thrombocytopenia cases with a platelet count
< 50 × 103/µl were found in patients with ITP. This is consistent with the accepted parameters
for a differential diagnosis of GT and ITP. The timing of the initial diagnosis was
found to be compatible with the etiological factors as most of the patients with ITP
and GT were diagnosed during the 1st and 3rd trimester, respectively. The rate of
diagnosis during the 1st trimester in GT patients was found to be 1.5%, while previous
studies have shown rates as high as 23.1% [21].
The reduction of Hb levels according to etiological factors showed no statistical
significance between groups. Four out of 385 (1%) underwent a hysterectomy due to
postpartum hemorrhage with moderate and mild thrombocytopenia. Thrombocytopenia in
pregnancy is not normally related to postpartum hemorrhage or increased rates of hysterectomy
in comparison to normal women [34]. In this study, hysterectomies were performed in patients with a diagnosis other
than ITP. This could be explained by the number of cases in each group and the relatively
small sample size in the ITP group. However, the rate of blood product transfusions
was significantly different between the groups in favor of an increased transfusion
rate in the ITP group (p < 0.001). This may also be explained by the platelet concentrate
transfusion requirements of these patients and the ongoing low platelet counts, occurring
even after delivery. In addition, the overall rate of administration of any kind of
blood product was found to be 9.9% which is slightly lower than that reported in previous
studies [35].
Analysis regarding the initial time of diagnosis revealed significantly lower platelet
counts in patients diagnosed during the 1st trimester compared with those diagnosed
during the 2nd and 3rd trimesters. This is consistent with the fact that most of the
patients with ITP were diagnosed during the 1st trimester which was the group with
the lowest platelet counts. Reduction of Hb levels was shown to be unrelated to the
initial diagnosis time. However, as with the etiological factors, a statistically
significant difference in Hb reduction was not observed between groups (0.985). Patients
initially diagnosed during their 1st trimester were found to require more transfusions
compared with those diagnosed during the 2nd and 3rd trimesters. This is most likely
due to different onsets of the disease with the different etiological factors. Similarly,
the transfusion requirements were significantly higher in patients with severe thrombocytopenia
which consisted only of patients with ITP in this study. Conflicting results on the
relationship between the severity of thrombocytopenia and adverse outcomes have been
reported. Despite the findings of this study, it has been reported that the severity
of GT is not associated with adverse outcomes [36]. Conversely, severe thrombocytopenia was found to be related to adverse outcomes
in previous studies that were similar to the present study [37], [38].
Analysis regarding the rate of thrombocytopenia in newborns and the median values
of newborn platelet counts showed no significant difference between groups regarding
etiological factors, gestational week at diagnosis, and severity of the disease. Despite
the lack of statistical significance, neonatal thrombocytopenia occurred in 50% of
the cases with severe thrombocytopenia which consisted of patients with ITP. These
findings are also consistent with previous studies showing that patients with ITP
were the most likely to have a newborn with thrombocytopenia at a rate between 15
and 25%; however, women with ITP should not be discouraged from having babies [39], [40]. Furthermore, in our cohort none of the newborns with thrombocytopenia had a severe
bleeding complication or intracranial hemorrhage. The low risk of complications related
to newborns is also consistent with previous studies showing low rates of newborn
complications [41]. The study has also concluded that predicting thrombocytopenia in newborns is challenging,
as there is a lack of significant differences regarding analysis including etiological
factors, time of initial diagnosis, and severity of the disease.
Limitations of this study include the retrospective study design and an imbalance
between the case numbers of each group. Although we aimed to obtain a complete dataset
for all the patients included in the study, some data were not available for certain
parameters. However, prepregnancy and postpartum follow-ups of the patients were carefully
evaluated to effectively define etiological factors. The evaluation of several factors,
including neonatal factors, is a strength of this study.
In conclusion, thrombocytopenic pregnancies must be carefully evaluated in terms of
the severity of thrombocytopenia, gestational period of the initial diagnosis, and
etiological reasons. In particular, patients with ITP must be carefully evaluated
since these pregnancies are more likely to require transfusions and have platelet
counts < 50 × 103/µl. The lack of any relationship between neonatal platelets and etiological factors
must also be kept in mind and all neonates born to thrombocytopenic mothers must be
carefully evaluated despite the fact that outcomes of neonatal thrombocytopenia are
found to be favorable.
